Role of extracellular vesicles in tumour microenvironment

• Published in: Cell communication and signaling 2020-10, Vol.18 (1), p.163-163, Article 163
• Main Authors: Tao, Shi-Cong, Guo, Shang-Chun
• Format: Article
• Language: English
• Subjects: Angiogenesis; Biopsy; Biosynthesis; Body fluids; Chemoresistance; Communication; Cytokines; Drug delivery; Extracellular matrix; Extracellular vesicles; Gene expression; Growth factors; Immunotherapy; Ligands; Lipid biopsy; Lipids; Literature reviews; Mesenchyme; Metastases; Metastasis; MicroRNAs; Non-coding RNAs; Plasma; Protein transport; Proteins; Review; Signal transduction; Transport media; Tumor microenvironment; Tumors; Tumour microenvironment
• ISSN: 1478-811X; 1478-811X
• DOI: 10.1186/s12964-020-00643-5

In recent years, it has been demonstrated that extracellular vesicles (EVs) can be released by almost all cell types, and detected in most body fluids. In the tumour microenvironment (TME), EVs serve as a transport medium for lipids, proteins, and nucleic acids. EVs participate in various steps involved in the development and progression of malignant tumours by initiating or suppressing various signalling pathways in recipient cells. Although tumour-derived EVs (T-EVs) are known for orchestrating tumour progression via systemic pathways, EVs from non-malignant cells (nmEVs) also contribute substantially to malignant tumour development. Tumour cells and non-malignant cells typically communicate with each other, both determining the progress of the disease. In this review, we summarise the features of both T-EVs and nmEVs, tumour progression, metastasis, and EV-mediated chemoresistance in the TME. The physiological and pathological effects involved include but are not limited to angiogenesis, epithelial-mesenchymal transition (EMT), extracellular matrix (ECM) remodelling, and immune escape. We discuss potential future directions of the clinical application of EVs, including diagnosis (as non-invasive biomarkers via liquid biopsy) and therapeutic treatment. This may include disrupting EV biogenesis and function, thus utilising the features of EVs to repurpose them as a therapeutic tool in immunotherapy and drug delivery systems. We also discuss the overall findings of current studies, identify some outstanding issues requiring resolution, and propose some potential directions for future research. Video abstract.